News

BC Platforms announced that it has closed a USD $15 million financing round alongside a new commercial collaboration with IQVIA. The round was led by IQVIA in conjunction with…
Read More...

Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical…
Read More...

Global Blood Therapeutics, Inc. and Syros Pharmaceuticals, Inc. announced that they have entered into a collaboration to discover, develop and commercialize novel therapies for sickle…
Read More...

Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut Technology, have announced a…
Read More...

Dicerna Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan drug designation to Dicerna’s DCR-A1AT for the treatment of congenital alpha-1 antitrypsin…
Read More...

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, and the Sean M.…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor…
Read More...

Shandong Fontacea Pharmaceutical Co. Ltd. announced that it has entered into an exclusive license, development and commercialization agreement with Janssen Biotech, Inc., to develop and…
Read More...

BioArctic AB (publ) announced the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The…
Read More...

Triplet Therapeutics, Inc., a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, launched today with $59 million in…
Read More...

CytoDyn Inc. and Vyera Pharmaceuticals, LLC announced that they have entered into a Commercialization and License Agreement (CLA) and a related Supply Agreement to commercialize…
Read More...

Roche and Spark Therapeutics, Inc. announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger…
Read More...

AstraZeneca and MSD Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that the US Food and Drug Administration (FDA) Oncologic Drugs…
Read More...

Organovo Holdings, Inc. and Tarveda Therapeutics, a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines,…
Read More...

UMass Medical School and GE Healthcare Life Sciences will establish a new large-scale viral vector manufacturing facility, able to provide large quantities of high-quality recombinant…
Read More...

Charles River Laboratories International, Inc. and HemaCare Corporation announced a definitive agreement for Charles River to acquire HemaCare for approximately $380 million in cash.…
Read More...

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI (enzalutamide) for the…
Read More...

Boehringer Ingelheim and Eli Lilly and Company announced results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to functional endpoints with Jardiance (empagliflozin)…
Read More...

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced it has made regulatory submissions to both the…
Read More...

Pfizer Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of…
Read More...